BOSTON and ROLLE, Switzerland, July 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today announced that L'hôpital Universitaire Avicenne is implementing the SOPHiA DDM™ Platform. The hospital, located in Bobigny, France, will use the platform to advance its testing and research of blood-related cancers and disorders. "As a research and teaching hospital, as well as a clinical center of excellence, it is our goal to ...

Core Insights - OncoHelix is the first laboratory in Canada to implement MSK-ACCESS® powered with SOPHiA DDM™, enhancing its oncology testing capabilities through advanced liquid biopsy solutions [1][4] - The partnership with SOPHiA GENETICS aims to leverage cutting-edge technology for rapid validation of genomic panels and sequencing, supporting OncoHelix's mission in precision oncology [3][4] Company Overview - OncoHelix, based in Calgary, Canada, specializes in genomic and molecular testing services globally and collaborates with the Hematology Translational Lab at the University of Calgary [2] - SOPHiA GENETICS is a cloud-native healthcare technology company focused on data-driven medicine, providing the SOPHiA DDM™ platform for analyzing complex genomic data [6] Technology and Innovation - The MSK-ACCESS® powered with SOPHiA DDM™ is a decentralized ctDNA assay developed by Memorial Sloan Kettering Cancer Center, analyzing 146 key cancer-associated genes [4] - Liquid biopsy testing offers a less invasive alternative to traditional solid tumor biopsies, extracting cell-free DNA from blood plasma to reveal circulating tumor DNA [3]

Core Insights - OncoHelix is the first laboratory in Canada to implement MSK-ACCESS® powered with SOPHiA DDM™, enhancing its genomic and molecular testing capabilities [1][8] - The partnership with the Hematology Translational Lab at the University of Calgary has significantly advanced precision oncology and immunology research [1] - Liquid biopsy testing, which extracts cell-free DNA from blood plasma, offers a less invasive alternative to traditional biopsies, facilitating quicker clinical decisions and monitoring [2][9] Company Developments - OncoHelix will utilize the new liquid biopsy solution to enhance its oncology testing capabilities, building on its existing use of the SOPHiA DDM™ Platform for myeloid testing [8][9] - The MSK-ACCESS® powered with SOPHiA DDM™ is a decentralized ctDNA assay developed by Memorial Sloan Kettering Cancer Center, focusing on deep sequencing of 146 cancer-associated genes [9] - The implementation of this technology is expected to improve the assessment of cancer treatment responses and the diagnosis of cases where tissue biopsy is not feasible [3][9] Industry Context - SOPHiA GENETICS is a leader in data-driven medicine, utilizing AI to provide actionable insights for healthcare institutions globally [5] - The collaboration between OncoHelix and SOPHiA GENETICS reflects a growing trend in the healthcare industry towards integrating advanced genomic technologies to improve patient care [9]

BOSTON and ROLLE, Switzerland, July 23, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the second quarter of fiscal year 2024 before U.S. markets open on Tuesday, August 6, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webc ...

BOSTON and ROLLE, Switzerland, June 24, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (NASDAQ:SOPH), a healthcare technology company and a leader in data-driven medicine, is pleased to announce that its annual general meeting of shareholders (the "AGM") was held at the Company's headquarters, La Piece 12, 1180 Rolle/VD, Switzerland, earlier today at 14:00 CEST (8:00 a.m. EDT). About SOPHiA GENETICS Investors Contact: Kellen Sanger IR@sophiagenetics.com The Company would like to thank all shareholders represen ...

Novel application supports measurable residual disease (MRD) testing to help monitor cancer and stay ahead of relapse BOSTON and ROLLE, Switzerland, June 24, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced its new Residual Acute Myeloid (RAM) Application. The new offering expands the company's comprehensive oncology portfolio to support measurable residual disease (MRD) capabilities and will be ava ...

New collective intelligence network to enable the most advanced research in oncology in support of precision medicine BOSTON and ROLLE, Switzerland, May 30, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced SOPHiA UNITY, a new data-driven consortium designed to accelerate cancer research globally. SOPHiA UNITY aims to bring together leading healthcare institutions to progress a shared goal of further ...

In collaboration with Microsoft and NVIDIA, SOPHiA GENETICS is developing a comprehensive whole genome analytical solution BOSTON and ROLLE, Switzerland, May 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that it is collaborating with Microsoft and NVIDIA to leverage their expertise in technology and genomics to bring a streamlined and scalable whole genome sequencing (WGS) analytical solution ...

"At SOPHiA GENETICS we are committed to accelerating and expanding the use of precision medicine," said Ricardo Mendonca Filho, PhD., Managing Director, LAPAC, SOPHiA GENETICS. "Instituto Mário Penna is a staple within the cancer-care community in Brazil, and its implementation of the SOPHiA DDM™ Platform shows its commitment to advancing cancer care. We are confident that our AI-based platform will help Instituto Mário Penna generate fast, accurate, and meaningful insights to support researchers and clinic ...

"Precision medicine makes novel therapies for cancer treatment possible," said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS. "The implementation of the SOPHiA DDM™ Platform will help Klinikum Klagenfurt am Wörthersee produce reliable insights from its testing while saving time and valuable resources." The SOPHiA DDM™ Platform will help broaden the hospital's cancer testing and diagnostic capabilities BOSTON and ROLLE, Switzerland, May 16, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cl ...